News | CT Angiography (CTA) | August 28, 2017

Philips to Develop FFR-Angiography in Partnership With HeartFlow

Global collaboration aims to accelerate access to tools to determine extent of coronary artery disease and improve patient care

Philips to Develop FFR-CT in Partnership With HeartFlow

August 28, 2017 — Philips Healthcare and HeartFlow Inc. announced they entered into a collaboration agreement to improve access to diagnostic and planning tools for interventional cardiologists evaluating and treating patients with suspected coronary artery disease (CAD). Under the agreement, Philips will promote the use of the HeartFlow FFR-CT (computed tomography) Analysis in conjunction with Philips' advanced catheters for imaging and assessing measurements of the inside of a patient's coronary arteries. 

The advanced catheters from Philips that will be promoted in conjunction with HeartFlow's technology include Philips' coronary fractional flow reserve (FFR), instant wave-free ratio (iFR) and intravascular ultrasound (IVUS) solutions.

Philips and HeartFlow's commercial collaboration will initially focus on the United States, with the intention to expand joint efforts globally in the near term. The two companies are also exploring further collaborations in diagnostic imaging and advanced informatics.

The HeartFlow FFR-CT analysis is the only commercially available noninvasive technology to provide insight into both the extent of CAD and the impact of the disease on blood flow to the heart. Data from a patient's non-invasive coronary CT angiogram are securely uploaded from the hospital's system to the cloud. HeartFlow leverages deep learning to create a personalized, digital 3-D model of a patient's coronary arteries, which is then analyzed by powerful computer algorithms to evaluate millions of complex equations to simulate blood flow in the model and assess the impact of blockages on coronary blood flow. The HeartFlow FFR-CT analysis technology provides results to the clinician via a secure web interface. To date, more than 13,000 patients have benefitted from the HeartFlow FFR-CT.[1]

In the United States, 16.8 million people are affected by CAD, which develops when the coronary arteries narrow, reducing blood flow to the heart.[2] CAD causes chest pain and heart attack and can lead to death. As part of a standard protocol, many of these patients are referred to the cardiac cath lab where more than half are discharged on medicines or non-treatment. Improvements in the non-invasive space have the potential to allow physicians to safely defer invasive testing, reducing risks to the patient and the overall cost of care for all.

"Our commitment is to transform the patient experience and identify pathways that are personalized, high quality and at a lower price point," said Christopher Barys, business leader of Philips image guided therapy devices. "To address the burden that CAD is placing on healthcare systems and to transform the patient experience, hospitals are focused on adopting new technology that can improve the diagnosis and care of these patients while reducing unnecessary invasive procedures. HeartFlow shares our mission of improving clinical outcomes and, through collaboration, we can advance our goal of helping healthcare providers decide, guide, treat and confirm the right therapy at the point of care."

Exclusive Agreement to Co-develop FFR-CT 

In addition to the commercial collaboration agreement between Philips and HeartFlow, the two companies have entered into an exclusive agreement to co-develop an improved cath lab X-ray angiography image derived FFR or iFR solution, to significantly enhance workflow while improving the diagnosis and subsequent treatment of patients with CAD. he solution will use angiographic imaging to create a derived FFR, similar to FFR-CT technology.

 

"Our collaboration agreement with Philips, which has an integrated solution within cath labs, will help bring HeartFlow's technology to more patients with suspected and potentially life-threatening CAD," said John H. Stevens, M.D., president and CEO of HeartFlow. "We look forward to continuing to address unmet needs in cardiology in collaboration with Philips to further support our goal of improving patient lives and reducing the total cost of care."

Philips' seamlessly integrated solutions, such as CORE IVUS and SyncVision, are valuable tools in the diagnosis of CAD. The HeartFlow FFR-CT analysis, is an additional diagnostic tool that expands clinicians' capabilities.

For more information: www.philips.com/newscenter

 

Related FFR and FFR-CT Content:

What is New in FFR Technology

GE Healthcare, HeartFlow Announce Cardiovascular CT Collaboration for FFR-CT

VIDEO: Implementation and the Science Behind FFR-CT

 

References: 

1. Douglas PS, DeBruyne B, Pontone G., Patel MR, et al. One-year outcomes of FFRCT-guided care in patients with suspected coronary disease: The PLATFORM Study. J Am Coll Cardiol. 2016;68(5),435-45. 

2. www.ncbi.nlm.nih.gov/pmc/articles/PMC2787400/

Related Content

An example of Viz.AI's pulmonary embolism AI application and mobile alert to the physician on-call. Viz.AI and Avicenna.AI Partner to Launch Artificial Intelligence Care Coordination for Pulmonary Embolism and Aortic Disease

An example of Viz.AI's pulmonary embolism AI application and mobile alert to the physician on-call. 

News | July 21, 2021
July 21, 2021 — Artificial int...
An example of HeartFlow's FFR-CT analysis of blockage severity in a patient's coronary vessels based on a cardiac CT scan.

An example of HeartFlow's FFR-CT analysis of blockage severity in a patient's coronary vessels based on a cardiac CT scan.

News | Cardiac Imaging | July 15, 2021
July 15, 2021 — HeartFlow, which has commercialized noninvasive...
The inherent spectral capabilities of Mayo Clinic's new third-generation photon-counting CT research scanner allows clear visualization of the intact portions of the coronary artery lumen (arrowhead) by reducing the bright signal from the dense coronary calcifications (arrows).

The inherent spectral capabilities of Mayo Clinic's new third-generation photon-counting CT research scanner allows clear visualization of the intact portions of the coronary artery lumen (arrowhead) by reducing the bright signal from the dense coronary calcifications (arrows). Spectral CT is able to bin photos on different energies that can be used to enhance or subtract chemical elements from the images based on their spectral signature, such as calcium shown here, and iodine.
 

News | Computed Tomography (CT) | July 14, 2021
July 14, 2021 — Performing the first cardiac scan on their new photon-counting detector...
ujifilm's robust medical systems portfolio includes a comprehensive product lineup covering CT, MRI, fluoroscopy, digital radiography, women’s health, ultrasound, systems integration, endoscopy and endosurgery, enterprise imaging, assisted reproductive technology, cell culture media, cell therapy development, In-Vitro diagnostics (IVD), and investigational drug development
News | Radiology Imaging | July 14, 2021
July 14, 2021 — Fujifilm announced the launch of the ...
NeuroLogica joins forces with Massachusetts General Hospital to pilot OmniTom Elite with Photon Counting Detector (PCD) technology at patient point-of-care

NeuroLogica joins forces with Massachusetts General Hospital to pilot OmniTom Elite with Photon Counting Detector (PCD) technology at patient point-of-care. (Photo: Business Wire)

News | Computed Tomography (CT) | July 13, 2021
July 13, 2021 — NeuroLogica Corp.
Nearly one quarter of deaths from lung cancer could be avoided in high-risk populations through the adoption of targeted screening with low-dose computed tomography (LDCT) scans, as based on the results of the NELSON study.

Getty Images

News | Computed Tomography (CT) | July 11, 2021
July 11, 2021 — The report ‘Lung Cancer Screening: The Cost of Inaction’ shows that lung cancer screening pres